Literature DB >> 19165450

[Bisphosphonates and osteonecrosis of the jaw--an increasing challenge in palliative care].

Dora Beke1, Martin Pecherstorfer.   

Abstract

Bone metastases are one of the most common complications of cancer. Up to 70% of patients with advanced breast cancer metastasize to the bone. The standard long-term treatment of bone metastases is bisphosphonates. This effective therapy, however, is able to cause serious side effects. Osteonecrosis of the jaw (ONJ) is a recently detected adverse outcome associated in rare cases with bisphosphonate therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19165450     DOI: 10.1007/s10354-008-0630-z

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  19 in total

Review 1.  Mechanisms of bone metastasis.

Authors:  G David Roodman
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

2.  Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid.

Authors:  Meletios A Dimopoulos; Efstathios Kastritis; Athanasios Anagnostopoulos; Ioannis Melakopoulos; Dimitra Gika; Lia A Moulopoulos; Christina Bamia; Evangelos Terpos; Konstantinos Tsionos; Aristotelis Bamias
Journal:  Haematologica       Date:  2006-06-01       Impact factor: 9.941

3.  Bisphosphonates and jaw osteonecrosis in patients with advanced breast cancer.

Authors:  G Sanna; L Preda; R Bruschini; M Cossu Rocca; S Ferretti; L Adamoli; E Verri; L Franceschelli; A Goldhirsch; F Nolè
Journal:  Ann Oncol       Date:  2006-08-25       Impact factor: 32.976

4.  Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: a single-centre experience in 303 patients.

Authors:  Kostas Zervas; Evgenia Verrou; Zisis Teleioudis; Konstantinos Vahtsevanos; Anastasia Banti; Dimitra Mihou; Dimitris Krikelis; Evangelos Terpos
Journal:  Br J Haematol       Date:  2006-08-01       Impact factor: 6.998

5.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group.

Authors:  R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma
Journal:  J Clin Oncol       Date:  1999-03       Impact factor: 44.544

6.  Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.

Authors:  Michael F X Gnant; Brigitte Mlineritsch; Gero Luschin-Ebengreuth; Stephan Grampp; Helmut Kaessmann; Marianne Schmid; Christian Menzel; Jutta Claudia Piswanger-Soelkner; Arik Galid; Martina Mittlboeck; Hubert Hausmaninger; Raimund Jakesz
Journal:  J Clin Oncol       Date:  2006-12-11       Impact factor: 44.544

7.  Primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin.

Authors:  D Y Graham; H M Malaty; R Goodgame
Journal:  Am J Gastroenterol       Date:  1997-08       Impact factor: 10.864

8.  Bisphosphonate-associated osteonecrosis of the jaw in patients with multiple myeloma and breast cancer.

Authors:  E Nastro; C Musolino; A Allegra; G Oteri; M Cicciù; A Alonci; E Quartarone; C Alati; F S De Ponte
Journal:  Acta Haematol       Date:  2006-12-12       Impact factor: 2.195

9.  Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

Authors:  Daniele Santini; Bruno Vincenzi; Giordano Dicuonzo; Giuseppe Avvisati; Cristian Massacesi; Fabrizio Battistoni; Michele Gavasci; Laura Rocci; Maria Cristina Tirindelli; Vittorio Altomare; Massimo Tocchini; Maurizio Bonsignori; Giuseppe Tonini
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

Review 10.  Bisphosphonates: a review of their pharmacokinetic properties.

Authors:  J H Lin
Journal:  Bone       Date:  1996-02       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.